Progenics Pharmaceuticals has found a new partner for its opioid-induced constipation (OIC) drug Relistor® (methylnaltrexone bromide) in the form of Salix Pharmaceuticals. Salix receives the global rights to the drug, excluding Japan, in a deal that is potentially worth more than US$350 M to Progenics. Relistor was previously licensed to Wyeth but Progenics regained the rights to the product in late 2009. Salix will assume development and commercialisation responsibility for the drug from April 2011.